Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor with a long half-life, high selectivity, and rapid onset of action. Because the safety of using PDE5 inhibitors as therapeutic agents for fetal growth restriction (FGR) has been a problem worldwide, this paper primarily focuses on the safety assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Maki, Shintaro, Tanaka, Hiroaki, Tsuji, Makoto, Furuhashi, Fumi, Magawa, Shoichi, Kaneda, Michiko K., Nii, Masafumi, Tanaka, Kayo, Kondo, Eiji, Tamaru, Satoshi, Ogura, Toru, Nishimura, Yuki, Endoh, Masayuki, Kimura, Tadashi, Kotani, Tomomi, Sekizawa, Akihiko, Ikeda, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617029/
https://www.ncbi.nlm.nih.gov/pubmed/31208060
http://dx.doi.org/10.3390/jcm8060856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617029/
https://www.ncbi.nlm.nih.gov/pubmed/31208060
http://dx.doi.org/10.3390/jcm8060856

Ejemplares similares